click below
click below
Normal Size Small Size show me how
Hepatitis drugs
hepatitis drugs
| Question | Answer |
|---|---|
| Lamivuridine (NucleoSide analog) MOA | inhibits HBV DNA polymerase via chain termination/ some anti-HIV activity |
| Lamivuridine PK | Renally eliminated/ no drug interactions |
| Lamivuridine dosing | oral/ once daily |
| Lamivuridine AE | none |
| Adefovir (NucleoTide analog) MOA | inhibits HBV DNA polymerase via chain termination/ some anti-HIV activity |
| Adefovir PK | prodrug/ renally eliminated/no drug interactions |
| Adefovir AE | gradual delayed renal toxicity (avoid w/ other renal toxic agents) increases SrCr and PO4!! |
| Entecavir (NucleoSide analog) MOA | inhibits HBV DNA polymerase via chain termination AND may inhibit other ways also!!!**** |
| Entecavir PK | W/O Food/ renally eliminated |
| Entecavir dosing | oral/ once daily |
| Entecavir AE | nothing |
| Telbivudine (NucleoSide analog) MOA | inhibits HBV DNA polymerase via chain termination |
| Telbivudine PK | renally elimanted |
| Telbivudine dosing | oral/ once daily |
| Telbivudine AE | little maybe myopathy (small %) or increasesed CK |
| Tenofovir (NucleoTide analog) MOA | inhibits HBV DNA polymerase via chain termination |
| Tenofovir PK | renally eliminated |
| Tenofovir dosing | oral/ once daily |
| Tenofovir AE | not much maybe osteoporosis/ renal toxicity |
| Tenofovir against HIV | fully active against HIV at normal dose |
| NucleoTide analogs against HBV | adefovir, tenofovir |
| NucleoSide analogs against HBV | lamivudine, Entecavir, Telbivudine |
| Interferon MOA | inhibit viral replication and enhances MHC |
| Pegylated alpha interferons (PEG) PK | hepatically cleared (steady state at 5-8 weeks |
| PEG Dosing | subQ weekly, some viruses may have different genotype and alter treatment |
| PEG AE | high %/ flu-like symptoms/ psychiatric/ many more |
| PEG drug interactions | decreases clearance of theophylinne and methadone and increases suppression of other myelosuppresive agents |
| PEG used in what | HBV/ HCV |
| Ribavirun MOA | inhibits RNA in virus |
| Ribavirun PK | renally |
| Ribavirun dosing | 2x a day w/ food / caution in renal insufficient |
| Ribuvirun AE | anemia, teratogenic and carcinogenic, skin rash, GI symptoms |
| Ribuvirun drug interactions | with other myelosuppresive agents (IFN) |
| Ribuvirun directions | must be given with IFN |